Penbrook Management Exits Position in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Penbrook Management has sold out all of its stake in Gilead Sciences during the most recent quarter, according to the disclosure filed by the company on Apr 21, 2016 with the SEC. The investment management company has sold out 2,000 shares of Gilead Sciences which is valued at $203,860.

Gilead Sciences closed down -0.61 points or -0.60% at $100.72 with 85,85,754 shares getting traded on Wednesday. Post opening the session at $101.3, the shares hit an intraday low of $100.15 and an intraday high of $101.78 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Appleton Partners Incma boosted its stake in GILD in the latest quarter, The investment management firm added 70,047 additional shares and now holds a total of 83,414 shares of Gilead Sciences which is valued at $8,502,389. Gilead Sciences makes up approx 1.66% of Appleton Partners Incma’s portfolio.Umb Bank N Amo boosted its stake in GILD in the latest quarter, The investment management firm added 5,936 additional shares and now holds a total of 188,305 shares of Gilead Sciences which is valued at $19,193,929. Gilead Sciences makes up approx 0.81% of Umb Bank N Amo’s portfolio.Cue Financial Group boosted its stake in GILD in the latest quarter, The investment management firm added 2,420 additional shares and now holds a total of 9,929 shares of Gilead Sciences which is valued at $975,921. Gilead Sciences makes up approx 0.84% of Cue Financial Group’s portfolio.Cedar Hill Associates boosted its stake in GILD in the latest quarter, The investment management firm added 930 additional shares and now holds a total of 35,783 shares of Gilead Sciences which is valued at $3,517,111. Gilead Sciences makes up approx 0.61% of Cedar Hill Associates’s portfolio.Community Trust Investment Co boosted its stake in GILD in the latest quarter, The investment management firm added 36,874 additional shares and now holds a total of 101,536 shares of Gilead Sciences which is valued at $9,730,195. Gilead Sciences makes up approx 1.26% of Community Trust Investment Co’s portfolio.

On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.